ClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion

Bulletin Express

昨天

ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.

JD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.

The Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1151645734"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151645734\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151645734?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151645734","market":"us","top_or_hot":-1,"title":"ClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion","media":"Bulletin Express","content":"<p>ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.</p>\n<p>JD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.</p>\n<p>The Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-13 12:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.</p>\n<p>JD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.</p>\n<p>The Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09955","symbol_name":"智云健康","start_time":0,"source_url":"","article_id":"1151645734","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151645734","pubTimestamp":1763007793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09955":"智云健康"},"translate_title":"ClouDr(9955.HK)与京东健康(6618.HK)签署在线医药扩张服务合作协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09955":1},"content_text":"ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.\nJD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.\nThe Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}